Lushoto/Rombo. Four out of every ten secondary schools in Tanzania lack the minimum laboratory infrastructure required to deliver practical science education, undermining the country’s efforts to ...

Jason Fernando is a professional investor and writer who enjoys tackling and communicating complex business and financial problems. Eric's career includes extensive work in both public and corporate ...

Jill Blumberg of Practical Law asked leading real estate practitioners to share their thoughts on recent developments impacting the US commercial real estate market. Jennifer Chavez Jennifer is a ...

Once deployed, a challenge arises: people don’t use systems because they don’t trust them. Arionkoder solves this by ...

Altimmune (ALT) is advancing pemvidutide, a dual GLP-1/glucagon agonist, into a pivotal Phase 3 MASH trial in 2026.

Novo Nordisk plunges after CagriSema REDEFINE 4 misses vs. tirzepatide. Click here to read my most recent analysis of NVO stock.

Xenon Pharmaceuticals (XENE) stock soared 40% after Phase 3 trial data for azetukalner exceeded expectations in focal onset seizures. FDA filing set for Q3 2026.

February 6, 2026 • Most of parenting has very little to do with our kids.In this episode, we explore how our childhood experiences show up in moments of parenting stress, why everyday parenting ...

Level 1 Snow Emergency: Roadways are hazardous with blowing and drifting snow. Roads are also icy; drive carefully. Level 2 Snow Emergency: Roadways are hazardous with blowing and drifting snow. Only ...

A 2026 Informational Overview of the BreezeMeds Compounded GLP-1 Telehealth Weight Loss Platform, Semaglutide and Tirzepatide Medication Formats, Published Pricing Structure, 503A Compounding Pharmacy ...